| Primary endpoints in pediatric efficacy trials submitted to the US FDA DJ Green, JM Burnham, P Schuette, XI Liu, BM Maas, L Yao, SK McCune, ... The Journal of Clinical Pharmacology 58 (7), 885-890, 2018 | 23 | 2018 |
| A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs KL Garrett, J Chen, BM Maas, ML Cottrell, HA Prince, C Sykes, ... Journal of Pharmacology and Experimental Therapeutics 367 (2), 245-251, 2018 | 20 | 2018 |
| A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking … BM Maas, Y Cao Mabs 10 (8), 1322-1331, 2018 | 16 | 2018 |
| RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development: 1384. B Maas, A Aliprantis, D Wolford, G Fayad, K Vora, D Geng, H Ma, L Caro Open Forum Infectious Diseases 5, 2018 | 16 | 2018 |
| 1971. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK … A Aliprantis, D Wolford, L Caro, B Maas, H Ma, K Vora, D Geng, R Railkar, ... Open Forum Infectious Diseases 5 (suppl_1), S572-S572, 2018 | 10 | 2018 |
| Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. JB Dumond, SA Greene, HMA Prince, J Chen, BM Maas, C Sykes, ... Antiviral therapy 24 (1), 45-50, 2019 | 6 | 2019 |
| Bone mineral density to assess pediatric bone health in drug development BM Maas, J Wang, F Cooner, D Green, Y Yuan, L Yao, GJ Burckart Therapeutic innovation & regulatory science 51 (6), 756-760, 2017 | 5 | 2017 |
| Concentrations of pro-inflammatory cytokines are not associated with senescence marker p16INK4a or predictive of intracellular emtricitabine/tenofovir metabolite and endogenous … BM Maas, O Francis, KR Mollan, C Lee, ML Cottrell, HMA Prince, C Sykes, ... PloS one 11 (12), 2016 | 5 | 2016 |
| Tenofovir Alafenamide (TAF) for HIV Prevention in IV Drug Users K Garrett, B Maas, M Cottrell, H Prince, C Sykes, A Schauer, N White, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S88-S89, 2017 | | 2017 |
| Population Pharmacokinetics of Tenofovir (TFV) and Tenofovir Diphosphate (TFVdp) in the Blood, Semen, and Mononuclear Cells of HIV-Negative and Positive Men Receiving Tenofovir … SA Greene, J Chen, H Prince, B Maas, K Maffuid, K Garrett, C Sykes, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S113-S113, 2017 | | 2017 |
| A Minimal Physiologically-Based Pharmacokinetic Model to Investigate FcRn-Mediated mAb Recycling: Effect of K-on, K-off, Endosome Trafficking, and Animal Species B Maas, Y Cao JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 43, S50-S51, 2016 | | 2016 |
| A PK/PD Model to Predict Effective HIV PrEP Dosing Strategies for IV Drug Users ML Cottrell, J Chen, BM Maas, H Prince, C Sykes, N White, ADM Kashuba, ... AIDS RESEARCH AND HUMAN RETROVIRUSES 32, 356-356, 2016 | | 2016 |
| Comparison Between Two Methods For The Assessment Of Equivalence In Clinical Efficacy Of Inhaled Formoterol B Kandala, L Hendeles, B Maas, R Joseph, L Winner, G Hochhaus JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 41, S94-S95, 2014 | | 2014 |
Julie B. DumondUNC Eshelman School of PharmacyVerified email at unc.edu
